US › Healthcare

Enanta Pharmaceuticals Inc (ENTA)

US · Healthcare · Biotechnology

$13.32+2.86%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$17.2M
Revenue YoY
+15.0%
Net profit
$-13.1M
Profit YoY
+42.2%
EPS
$-0.45
EPS estimate
$-0.57
Net margin
-76.3%

EPS came in at -0.45 against a street estimate of -0.57 — a beat of 21.1%.

Key statistics

Market cap
$366.4M
Forward P/E
44.1
P/B
3.13
Book value
$4.01
EPS (TTM)
$-2.59
52-week high
$17.15
52-week low
$6.45
50-day MA
$13.08
200-day MA
$13.31
Beta
0.97

Analyst view

Analysts rate Enanta Pharmaceuticals Inc a buy (3 buy, 2 hold, 1 sell out of 6) with an average price target of $21.17.

Shareholding

Insiders
4.68%
Institutions
92.88%

Largest institutional holders

FundStake
HHG PLC13.01%
BlackRock Inc10.67%
Farallon Capital Management, L.L.C.9.88%
Krensavage Asset Management, LLC9.86%
Deep Track Capital, LP6.73%
Vanguard Capital Management, LLC4.05%
Vanguard Portfolio Management, LLC3.26%
Spruce Street Capital LP3.21%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Enanta Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.